Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B

        Epigenic Therapeutics to present recent anti-HBV project update at 2024 annual conference of AASLD

        Epigenic Therapeutics Announced to be listed in“Forbes Asia 100 To Watch 2024”

        Epigenic Therapeutics to present preclinical update of company's epigenome modulation technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the Liver

        Epigenic Therapeutics to Present Company's Epigenetic Modulation Technology in Enhancement of CAR-T Function at SITC 2023

        Epigenic Therapeutics to Present Company's Leading Drug Discovery Program Using Epigenetic Modulation Technology at ESGCT 2023

        Epigenic Therapeutics to Participate in the Chardan 7th Annual Genetic Medicines Conference

        Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development

        Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy

        SITC-poster：Epigenetic editing as a promising strategy to enhance efficacy and genomic integrity of CAR T cell therapy

        ESGCT-poster：Profound and Durable Silencing of PCSK9 in Non-Human Primates by Epigenome Modulation